DRI Healthcare TrustDHTRF 33 Market Cap is $674.5 Mil as of Jul. 04, 2026. GuruFocus rates DHTRF with a GF Score™ of 33/100 and a GF Value™ of $13.28 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,024 Drug Manufacturers companies, DRI Healthcare Trust ranks better than 66.99% on this metric.
DRI Healthcare Trust's quarterly market cap
increased
from Sep. 2025 ($600.0 Mil) to Dec. 2025 ($660.9 Mil) and
increased
from Dec. 2025 ($660.9 Mil) to Mar. 2026 ($664.1 Mil).
DRI Healthcare Trust's annual market cap
declined
from Dec. 2023 ($507.2 Mil) to Dec. 2024 ($464.5 Mil) but then
increased
from Dec. 2024 ($464.5 Mil) to Dec. 2025 ($660.9 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. DRI Healthcare Trust's Enterprise Value for Today is $1,078.0 Mil.
DRI Healthcare Trust (OTCPK:DHTRF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
DRI Healthcare Trust Market Cap Related Terms
DRI Healthcare Trust Market Cap Historical Data
* Premium members only.
The historical data trend for DRI Healthcare Trust's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DRI Healthcare Trust's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DRI Healthcare Trust Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DRI Healthcare Trust's Market Cap distribution charts can be found below:
* The bar in red indicates where DRI Healthcare Trust's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
DRI Healthcare Trust's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DRI Healthcare Trust (DHTRF) has a Market Cap of $674.5 Mil as of Jul. 04, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on DRI Healthcare Trust and its competitors. According to the industry distribution chart, DRI Healthcare Trust ranks #338 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 33%.
Is DRI Healthcare Trust's Market Cap too high?
DRI Healthcare Trust's current Market Cap is $674.5 Mil. The Drug Manufacturers industry median Market Cap is 217.83. DRI Healthcare Trust's value of $674.5 Mil is 209.6% above this industry median. Based on the distribution chart, DRI Healthcare Trust ranks #338 out of 1024 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, DRI Healthcare Trust has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DRI Healthcare Trust's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, DRI Healthcare Trust ranks #338 out of 1024 companies for Market Cap. This puts DRI Healthcare Trust in the upper half of its industry. The industry median Market Cap is 217.83. DRI Healthcare Trust's value of $674.5 Mil is 209.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 217.83, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DRI Healthcare Trust's current Market Cap of $674.5 Mil is 209.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on DRI Healthcare Trust and its competitors. For the Drug Manufacturers industry, the median Market Cap is 217.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DRI Healthcare Trust's current Market Cap is $674.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DRI Healthcare Trust stock overvalued right now?
Based on GuruFocus' analysis, DRI Healthcare Trust (DHTRF) is currently considered Fairly Valued. The stock's GF Value™ is $13.28, compared to a current price of $12.70 — trading 4.4% below its estimated fair value. The current Market Cap is $674.5 Mil and 209.6% above the Drug Manufacturers industry median of 217.83. DRI Healthcare Trust's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For DRI Healthcare Trust (DHTRF), the current Market Cap is $674.5 Mil as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DRI Healthcare Trust (DHTRF) Overvalued in 2026?
Based on GuruFocus' analysis, DRI Healthcare Trust stock appears to be undervalued.
The current stock price of $12.70 is trading 4.4% below its estimated GF Value™ of $13.28.
GuruFocus considers DRI Healthcare Trust to be Fairly Valued.
Key valuation signals for DHTRF:
Market Cap: $674.5 Mil
GF Value™: $13.28 vs. price of $12.70 (4.4% below fair value)
Industry Position: 209.6% above the Drug Manufacturers median (#338 of 1024)
No single metric tells the full story. See the DHTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DRI Healthcare Trust is an open-ended trust that purchases royalty entitlements on products that address unmet medical needs, providing its unitholders with top-line exposure to a portfolio of therapeutics. Its portfolio comprises several royalty streams on products that treat conditions in a number of therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, as well as lysosomal storage disorders (LSD) and immunology. The Trust has concluded that it operates as one segment, focused on acquiring royalty assets. Geographically, it generates maximum royalty income from the sale of products underlying its royalty agreements in the United States, followed by other markets such as Japan, the European Union, and the rest of the world.
33GF Score
Get the complete analysis for DHTRF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHTRF has been successfully added to your 
